Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Prevention

Cancer Prevention

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Recruitment strategies for lung cancer screening; a randomised trial in the 4-IN-THE-LUNG-RUN study.

Lung cancer (Amsterdam, Netherlands)·2026

Same author

How to Translate Quality Standards Into Good Lung Cancer Screening Programmes: The UK Experience.

British journal of hospital medicine (London, England : 2005)·2026

Same author

AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial.

Nature medicine·2026

Same author

Implementation of the NHS England Lung Cancer Screening Programme over 5 years.

Nature medicine·2026

Same author

A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer Screening.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Same author

Screening for lung cancer: A systematic review of overdiagnosis and its implications.

Molecular oncology·2025

Same journal

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026

Same journal

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026

Same journal

Co-medications and gut microbiome in NSCLC immunotherapy.

The Lancet. Oncology·2026

Same journal

Carcinogenicity of butyl benzyl phthalate, dibutyl phthalate, and diisononyl phthalate.

The Lancet. Oncology·2026

Same journal

New report sheds light on cancer disparities in the USA.

The Lancet. Oncology·2026

Same journal

Review highlights gaps in South Africa's cancer care.

The Lancet. Oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

CT screening for lung cancer: countdown to implementation.

John K Field¹, David M Hansell, Stephen W Duffy

¹Roy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre, Liverpool, UK.

The Lancet. Oncology

|November 27, 2013

Summary

This summary is machine-generated.

Lung cancer CT screening significantly reduces mortality. Further European trials are needed to inform international screening program implementation.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

Related Experiment Videos

Last Updated: May 5, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

Area of Science:

Pulmonology
Oncology
Public Health Policy

Background:

Lung cancer CT screening is a major policy consideration in the USA.
The US National Lung Screening Trial demonstrated significant reductions in lung cancer and all-cause mortality.
US organizations recommend widespread implementation of lung cancer screening.

Purpose of the Study:

To review current evidence on lung cancer CT screening.
To identify unanswered questions before European implementation.
To propose a UK demonstration trial.

Main Methods:

Review of existing evidence from lung cancer screening trials.
Analysis of mortality and cost-effectiveness data from the NELSON trial and pooled European trials.
Consideration of policy recommendations from US organizations.

Main Results:

US trials show a 20% reduction in lung cancer mortality and a 6.7% decrease in all-cause mortality.
European data from the NELSON trial and pooled European trials are pending.
A UK demonstration trial is proposed.

Conclusions:

The effectiveness of lung cancer CT screening is supported by US data.
Further European data is crucial for informing international screening policies.
A phased approach with demonstration trials may be beneficial for European implementation.